A number of other analysts have also recently weighed in on GSK. Shore Capital reissued a buy rating on shares of GlaxoSmithKline plc in a research note on Wednesday, June 1st. Beaufort Securities reissued a buy rating on shares of GlaxoSmithKline plc in a research note on Friday, June 3rd. Morgan Stanley set a GBX 1,500 ($19.58) target price on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research note on Tuesday, May 31st. BNP Paribas reissued a neutral rating and issued a GBX 1,560 ($20.36) target price on shares of GlaxoSmithKline plc in a research note on Thursday, August 4th. Finally, Liberum Capital reissued a buy rating and issued a GBX 1,900 ($24.80) target price on shares of GlaxoSmithKline plc in a research note on Tuesday, September 20th. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of GBX 1,676.44 ($21.88).
GlaxoSmithKline plc (LON:GSK) traded down 0.91% on Friday, hitting GBX 1638.00. The company’s stock had a trading volume of 2,002,336 shares. The company has a 50 day moving average price of GBX 1,652.33 and a 200-day moving average price of GBX 1,532.89. The company’s market capitalization is GBX 79.62 billion. GlaxoSmithKline plc has a 1-year low of GBX 1,227.50 and a 1-year high of GBX 1,716.50.
The firm also recently announced a dividend, which will be paid on Thursday, October 13th. Investors of record on Thursday, August 11th will be given a GBX 19 ($0.25) dividend. This represents a yield of 1.12%. The ex-dividend date is Thursday, August 11th.
In other news, insider Witty,Sir Andrew P sold 10,000 shares of GlaxoSmithKline plc stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43). Also, insider Slaoui,Moncef acquired 28 shares of the firm’s stock in a transaction dated Friday, August 12th. The stock was purchased at an average cost of GBX 2,208 ($28.82) per share, with a total value of £618.24 ($807.00).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.